Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Source: View publication →
The REWIND trial demonstrated that once-weekly subcutaneous dulaglutide significantly reduced the risk of major adverse cardiovascular events in a broad population of middle-aged and older adults with type 2 diabetes, most of whom did not have established cardiovascular disease.
Key Findings
Study Design
Study Limitations
Clinical Significance
The REWIND trial expanded the evidence base for GLP-1 receptor agonists by demonstrating cardiovascular benefit in a lower-risk primary prevention population, supporting the clinical use of dulaglutide as a disease-modifying therapy beyond glycemic control in patients with type 2 diabetes.
Historical Context
Prior to REWIND, cardiovascular outcome trials for GLP-1 receptor agonists (such as LEADER for liraglutide and SUSTAIN-6 for semaglutide) predominantly enrolled patients with established cardiovascular disease. REWIND was unique in its design by targeting a wider, older population with a higher proportion of participants who had cardiovascular risk factors but not prior cardiovascular events.
Guided Discussion
High-yield insights from every perspective
What is the physiological mechanism by which glucagon-like peptide-1 (GLP-1) receptor agonists like dulaglutide improve glycemic control, and how might these mechanisms indirectly contribute to the reduction in major adverse cardiovascular events (MACE)?
Key Response
GLP-1 agonists stimulate glucose-dependent insulin secretion, inhibit glucagon release, and slow gastric emptying. Beyond glycemic control, they promote weight loss, lower systolic blood pressure, and exert direct anti-inflammatory effects on the vascular endothelium, all of which likely contribute to the cardiovascular benefits observed in the REWIND trial.
The REWIND trial is unique among GLP-1 receptor agonist CVOTs due to its patient population. How does the proportion of patients with established cardiovascular disease in REWIND compare to the LEADER or SUSTAIN-6 trials, and how should this influence your management of a 60-year-old patient with T2DM and hypertension but no prior MI or stroke?
Key Response
Only 31.5% of REWIND participants had established CVD, compared to 81.3% in LEADER (liraglutide) and 73% in SUSTAIN-6 (semaglutide). REWIND provides the strongest evidence yet for the use of GLP-1 RAs in primary prevention for high-risk patients, suggesting we should consider these agents earlier in the disease course rather than waiting for a clinical event.
In the REWIND trial, the hazard ratio for the primary MACE outcome was 0.88. Upon analyzing the individual components of the composite endpoint, which component showed the most robust reduction, and what does this suggest about the potential organ-specific protective effects of dulaglutide compared to SGLT2 inhibitors?
Key Response
The benefit was largely driven by a reduction in non-fatal stroke (HR 0.76, 95% CI 0.61-0.95), while cardiovascular death and MI were not significantly reduced individually. This contrasts with SGLT2 inhibitors, which often show more pronounced benefits in heart failure and CV death, suggesting GLP-1 RAs may have a distinct role in neuroprotection or atherosclerotic stabilization.
Given the median follow-up of 5.4 years in REWIND—longer than most other GLP-1 RA trials—how does this extended duration impact your interpretation of the drug's safety profile and its long-term cost-effectiveness in a lower-risk primary prevention cohort?
Key Response
The longer follow-up provides greater confidence in the safety profile regarding rare events like medullary thyroid cancer or pancreatitis. From a cost-effectiveness perspective, while the absolute risk reduction is smaller in primary prevention, the long-term cumulative benefit in preventing stroke and renal decline may justify early intensive therapy in younger, high-risk populations.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
REWIND utilized a multicenter, randomized, double-blind, placebo-controlled design with a focus on 'real-world' representativeness. How does the trial's inclusion of a higher percentage of female participants and a lower baseline HbA1c (median 7.2%) impact the external validity and statistical power compared to trials that recruited higher-risk, more hyperglycemic cohorts?
Key Response
Including women (46%) and those with lower baseline HbA1c enhances generalizability to the broader T2DM population. However, a lower-risk population results in a lower event rate, requiring a longer study duration (5.4 years) and a larger sample size to achieve sufficient power to detect a significant difference in MACE compared to the placebo group.
The primary outcome HR in REWIND was 0.88 with a 95% CI of 0.79 to 0.99 (p=0.026). As a reviewer, how would you address the fragility of this p-value in the context of the trial’s massive sample size and the potential for a 'null' result if only a few events had shifted?
Key Response
The upper bound of 0.99 is very close to 1.0, indicating that the result, while statistically significant, is not highly robust. A reviewer would flag this 'marginal' significance and insist on a clear discussion of the effect size's clinical significance versus its statistical significance, especially given the costs and side effects of lifelong injectable therapy.
Based on the REWIND findings, should the ADA Standards of Care be updated to recommend GLP-1 RAs for all patients over 50 with T2DM and at least one additional risk factor, regardless of baseline HbA1c or CVD status?
Key Response
Current ADA guidelines (referencing REWIND) already moved toward recommending GLP-1 RAs with proven CV benefit for patients with multiple risk factors (primary prevention). REWIND's evidence supports a Level A recommendation for this broader group, shifting the focus from 'glucose-lowering' to 'organ-protection' regardless of the initial A1c level.
Clinical Landscape
Noteworthy Related Trials
EMPA-REG OUTCOME Trial
Tested
Empagliflozin 10/25mg daily
Population
T2DM patients with established CVD
Comparator
Placebo
Endpoint
3-point MACE
LEADER Trial
Tested
Liraglutide 1.8mg daily
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
SUSTAIN-6 Trial
Tested
Semaglutide 0.5/1.0mg weekly
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis